Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 2Pituitary Neoplasms 2Adenocarcinoma, Follicular 2Thyroid Neoplasms 1Pituitary ACTH Hypersecretion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 4fosbretabulin 3Radiotherapy 3selpercatinib 2Filgrastim 2Everolimus 2Doxorubicin 2Cisplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1sargramostim 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1mercaptoundecahydrododecaborate 1gallium Ga 68 dotatate 1fostamatinib 1entrectinib 1combretastatin 1alectinib 1aldesleukin 1Triiodothyronine 1Thyrotropin Alfa 1Thyrotropin 1Thalidomide 1Tamoxifen 1Semaxinib 1Rosiglitazone 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Rosiglitazone × Endocrine × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡